Site icon OncologyTube

Trials in HER2+ NSCLC – 2022 Program: Targeted Therapies Forum

Targeted Therapies Forum 2022, Breakout Session: In this video, Dr. Jeffrey Thompson examines results from several trials for HER2+ NSCLC treatments.

We thank our sponsors for this year’s support! #Novartis #Janssen #Blueprintmedicine #TakedaOncology #Astrazeneca #LillyOncology #genentech

For more, please visit http://cancerGRACE.org/.
To join the conversation, visit https://cancergrace.org/forum.

Exit mobile version